FGP
DNTH icon

Freestone Grove Partners’s Dianthus Therapeutics DNTH Stock Holding History

Freestone Grove Partners’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-239,943
Closed -$20.1M – 1112
2026
Q1 		$20.1M Buy
+239,943
New +$13.9M 0.14% 208

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Freestone Grove Partners's DNTH Position: Q2 2026 in Review

Freestone Grove Partners sold out of Dianthus Therapeutics (DNTH) in Q2 2026, closing a stake of 239,943 shares — an estimated $20.1M sold.

Freestone Grove Partners first reported a position in DNTH in Q1 2026 and held it in 1 quarter. The position peaked at $20.1M in Q1 2026. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Freestone Grove Partners reported no remaining Dianthus Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 239,943 Dianthus Therapeutics shares in Q2 2026, an estimated $20.1M.
  • Freestone Grove Partners first reported a position in Dianthus Therapeutics in Q1 2026 and held it in 1 quarter.
  • Freestone Grove Partners's Dianthus Therapeutics position peaked at $20.1M in Q1 2026.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.